MCM
BMY icon

Matarin Capital Management’s Bristol-Myers Squibb BMY Stock Holding History

Matarin Capital Management’s Portfolio BMY Stock Details BMY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		$2.53M Sell
40,822
-15,121
-27% -$930K 0.62% 72
2020
Q3 		$3.37M Sell
55,943
-598
-1% -$36K 0.71% 58
2020
Q2 		$3.33M Buy
+56,541
New +$3.38M 0.66% 64

Other funds holding BMY

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Berkshire Hathaway
Berkshire Hathaway Omaha, Nebraska $299B AUM 27.55% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return

Matarin Capital Management's BMY Position: Q4 2020 in Review

Matarin Capital Management reduced its Bristol-Myers Squibb (BMY) stake by 27% in Q4 2020, selling an estimated $930K and leaving 40,822 shares worth $2.53M. The position accounts for 0.62% of the portfolio, ranked #72.

Matarin Capital Management first reported a position in BMY in Q2 2020 and has held it in 3 quarters since. The position peaked at $3.37M in Q3 2020. 2,361 funds tracked by Wall St. Rank hold BMY as of Q4 2020.

  • Matarin Capital Management held 40,822 shares of Bristol-Myers Squibb worth $2.53M as of Q4 2020.
  • Matarin Capital Management sold 15,121 Bristol-Myers Squibb shares in Q4 2020, an estimated $930K.
  • Bristol-Myers Squibb made up 0.62% of Matarin Capital Management's portfolio in Q4 2020, its #72 holding.
  • Matarin Capital Management first reported a position in Bristol-Myers Squibb in Q2 2020 and has held it in 3 quarters since.
  • Matarin Capital Management's Bristol-Myers Squibb position peaked at $3.37M in Q3 2020.
  • 2,361 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q4 2020.

Based on Matarin Capital Management's 13F filing for Q4 2020, filed 3 Feb 2021.